Filing Details
- Accession Number:
- 0001013762-10-002999
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-12-08 16:00:21
- Reporting Period:
- 2010-12-06
- Filing Date:
- 2010-12-08
- Accepted Time:
- 2010-12-08 16:00:21
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1140098 | Advanced Cell Technology Inc. | ACTC | Pharmaceutical Preparations (2834) | 870656515 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1317093 | Robert Lanza | 33 Locke Drive Marlborough MA 01752 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.001 | Disposition | 2010-12-06 | 1,271,864 | $0.13 | 19,220,316 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.001 | Disposition | 2010-12-07 | 728,136 | $0.15 | 18,492,180 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Footnotes
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.132 to $0.1365, inclusive. The reporting person undertakes to provide to Advanced Cell Technology, Inc., any shareholder of Advanced Cell Technology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote.
- The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.145 to $0.1485, inclusive. The reporting person undertakes to provide to Advanced Cell Technology, Inc., any shareholder of Advanced Cell Technology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote.
Billionaire Hedge Funds
